JP2020515272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515272A5 JP2020515272A5 JP2019553883A JP2019553883A JP2020515272A5 JP 2020515272 A5 JP2020515272 A5 JP 2020515272A5 JP 2019553883 A JP2019553883 A JP 2019553883A JP 2019553883 A JP2019553883 A JP 2019553883A JP 2020515272 A5 JP2020515272 A5 JP 2020515272A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric polypeptide
- polypeptide
- complex
- fusion protein
- ectdomain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 105
- 102000004196 processed proteins & peptides Human genes 0.000 claims 104
- 229920001184 polypeptide Polymers 0.000 claims 103
- 108020001507 fusion proteins Proteins 0.000 claims 22
- 102000037865 fusion proteins Human genes 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 15
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims 14
- 241000700605 Viruses Species 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000000087 stabilizing effect Effects 0.000 claims 6
- 239000007864 aqueous solution Substances 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 238000006384 oligomerization reaction Methods 0.000 claims 4
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 241000712891 Arenavirus Species 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 2
- 229940021995 DNA vaccine Drugs 0.000 claims 2
- 101710189136 Envelope fusion protein Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229920002521 macromolecule Polymers 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000006337 proteolytic cleavage Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 102000004961 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 102000051366 Glycosyltransferases Human genes 0.000 claims 1
- 108700023372 Glycosyltransferases Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 230000005745 host immune response Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034197A JP2023071901A (ja) | 2017-03-30 | 2023-03-07 | キメラ分子およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901152A AU2017901152A0 (en) | 2017-03-30 | Chimeric molecules and uses thereof | |
| AU2017901152 | 2017-03-30 | ||
| PCT/AU2018/050299 WO2018176103A1 (en) | 2017-03-30 | 2018-03-29 | "chimeric molecules and uses thereof" |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034197A Division JP2023071901A (ja) | 2017-03-30 | 2023-03-07 | キメラ分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515272A JP2020515272A (ja) | 2020-05-28 |
| JP2020515272A5 true JP2020515272A5 (enExample) | 2021-05-20 |
| JP7291398B2 JP7291398B2 (ja) | 2023-06-15 |
Family
ID=63675061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553883A Active JP7291398B2 (ja) | 2017-03-30 | 2018-03-29 | キメラ分子およびその使用 |
| JP2023034197A Pending JP2023071901A (ja) | 2017-03-30 | 2023-03-07 | キメラ分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034197A Pending JP2023071901A (ja) | 2017-03-30 | 2023-03-07 | キメラ分子およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11254712B2 (enExample) |
| EP (2) | EP3601367B1 (enExample) |
| JP (2) | JP7291398B2 (enExample) |
| KR (1) | KR20190135017A (enExample) |
| CN (1) | CN110506060B (enExample) |
| AU (1) | AU2018241252B2 (enExample) |
| BR (1) | BR112019019813A2 (enExample) |
| CA (1) | CA3057171A1 (enExample) |
| DK (1) | DK3601367T3 (enExample) |
| ES (1) | ES3001108T3 (enExample) |
| IL (1) | IL269534B2 (enExample) |
| MX (1) | MX2019011599A (enExample) |
| PL (1) | PL3601367T3 (enExample) |
| SG (1) | SG11201908280SA (enExample) |
| WO (1) | WO2018176103A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009079796A1 (en) * | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
| SI3178490T1 (sl) | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| SI3275892T1 (sl) | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| CA3110842A1 (en) | 2018-02-15 | 2019-08-22 | Caretech Services Pty Ltd | A platform and system for use in therapeutic procedures |
| WO2020085457A1 (ja) * | 2018-10-25 | 2020-04-30 | Ｋｍバイオロジクス株式会社 | 改変ＣＭＶ ｇＢタンパク質及びこれを含むＣＭＶワクチン |
| EP3999107A1 (en) * | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4004018A1 (en) * | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| EP4086275A4 (en) * | 2019-12-31 | 2024-04-17 | Xiamen University | Multimerization delivery system for intracellular delivery of molecule |
| WO2021155733A1 (zh) * | 2020-02-05 | 2021-08-12 | 复旦大学 | 多肽、其制备方法和用途 |
| JP2023513135A (ja) * | 2020-02-06 | 2023-03-30 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 抗ラブドウイルス抗体を検出するのに有用なポリペプチド |
| CN112300251B (zh) * | 2020-02-24 | 2022-04-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白及疫苗 |
| WO2021216560A2 (en) * | 2020-04-20 | 2021-10-28 | Richard Ascione | Vaccine compositions for sars-related coronaviruses and methods of use |
| MX2022013934A (es) * | 2020-05-07 | 2023-02-22 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo. |
| MX2022015489A (es) * | 2020-06-10 | 2023-03-22 | Bavarian Nordic As | Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus. |
| US20230256090A1 (en) | 2020-06-29 | 2023-08-17 | Glaxosmithkline Biologicals Sa | Adjuvants |
| EP4192500A4 (en) * | 2020-08-10 | 2025-01-01 | The Scripps Research Institute | COMPOSITIONS AND METHODS RELATED TO EBOLAVIRUS VACCINES |
| US20240033343A1 (en) * | 2020-08-26 | 2024-02-01 | The University Of Queensland | Modified polypeptides with improved properties |
| US11175293B1 (en) * | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| US20240285755A1 (en) | 2021-05-24 | 2024-08-29 | Glaxosmithkline Biologicals Sa | Adjuvants |
| US20240317810A1 (en) * | 2021-07-15 | 2024-09-26 | Board Of Regents, The University Of Texas System | Prefusion-stabilized chimeric hmpv-rsv f proteins |
| US20230096087A1 (en) * | 2021-09-24 | 2023-03-30 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie | Prefusion-stabilized herpesvirus glycoprotein-b |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| KR20250011901A (ko) * | 2022-03-31 | 2025-01-22 | 더 유니버서티 어브 퀸슬랜드 | 개선된 키메라 폴리펩타이드 및 이의 용도 |
| WO2023196945A2 (en) * | 2022-04-08 | 2023-10-12 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof |
| AU2023339047A1 (en) | 2022-09-09 | 2025-03-20 | Repligen Corporation | Affinity agents |
| CN116789847B (zh) * | 2023-01-13 | 2024-04-16 | 广州医科大学附属第一医院（广州呼吸中心） | 融合蛋白、病毒样颗粒以及疫苗 |
| WO2024186980A2 (en) * | 2023-03-08 | 2024-09-12 | Dana-Farber Cancer Institute, Inc. | Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof |
| CN119978144B (zh) * | 2025-02-14 | 2025-10-17 | 嘉译生物医药(杭州)有限公司 | 一种hMPV病毒融合蛋白F变体、mRNA疫苗及其应用 |
| CN119841911B (zh) * | 2025-03-18 | 2025-10-28 | 北京华诺泰生物医药科技有限公司 | 一种人偏肺病毒f蛋白突变体及其应用 |
| CN120248083B (zh) * | 2025-06-05 | 2025-09-30 | 腾讯科技（深圳）有限公司 | Glp-1r和gcgr双靶点激活多肽或其衍生物、药学上可接受的盐及它们的用途 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| WO1992019266A1 (en) | 1991-05-06 | 1992-11-12 | The United States Of America, As Represented By The Department Of Health And Human Services | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6361770B1 (en) | 1994-09-23 | 2002-03-26 | University Of British Columbia | Method of enhancing expression of MHC class I molecules bearing endogenous peptides |
| JP3907698B2 (ja) | 1994-10-03 | 2007-04-18 | アメリカ合衆国 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
| FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| DE19650370A1 (de) | 1996-12-05 | 1998-06-10 | Basf Ag | Flammwidrige thermoplastische Formmassen auf der Basis von Polyarylenethern |
| US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| US6893866B1 (en) | 1997-11-28 | 2005-05-17 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| DK2272859T3 (en) | 1998-08-07 | 2015-01-19 | Univ Washington | Immunological herpes simplex virus antigens and methods for their use |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| JP2003530073A (ja) * | 1999-07-09 | 2003-10-14 | アメリカ合衆国 | 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造 |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| ES2256265T3 (es) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| US7569383B2 (en) | 2001-06-01 | 2009-08-04 | Acambis Inc. | Chimeric flavivirus vectors |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| DK1412493T3 (da) | 2001-08-02 | 2012-01-09 | Inst Clayton De La Rech | Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer |
| DE60233061D1 (de) | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
| RU2305708C2 (ru) | 2001-10-02 | 2007-09-10 | Энститю Клейтон Де Ля Решерш | Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| AU2002352913B2 (en) | 2001-11-30 | 2008-05-29 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen, and uses therefor |
| ES2602352T3 (es) | 2001-12-17 | 2017-02-20 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| US7081443B2 (en) * | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| RS53476B (sr) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| EP1858332A4 (en) | 2005-02-16 | 2011-06-22 | Lentigen Corp | LENTIVIRUS VECTORS AND ITS USE |
| KR20080052512A (ko) | 2005-05-23 | 2008-06-11 | 박신, 인크. | 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산 |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| US20090304641A1 (en) | 2005-10-17 | 2009-12-10 | Children's Hospital Boston | Methods and Compositions for Regulating Gene Expression |
| BRPI0504945B8 (pt) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. |
| US20070249043A1 (en) | 2005-12-12 | 2007-10-25 | Mayall Timothy P | Adenoviral expression vectors |
| US20100184832A1 (en) | 2006-07-14 | 2010-07-22 | Sanofi Pasteur Biologics Co. | Construction of Recombinant Virus Vaccines by Direct Transposon-Mediated Insertion of Foreign Immunologic Determinants into Vector Virus Proteins |
| CA2676719A1 (en) | 2007-02-09 | 2008-08-21 | Sanofi Pasteur Biologics Co. | Viral vectors and methods of use |
| WO2009019612A2 (en) | 2007-08-03 | 2009-02-12 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| US8815564B2 (en) | 2008-03-14 | 2014-08-26 | Sanofi Pasteur Biologics, Llc | Replication-defective flavivirus vaccines and vaccine vectors |
| US8871515B2 (en) | 2008-09-17 | 2014-10-28 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| PL3067064T3 (pl) * | 2008-12-09 | 2020-11-02 | Novavax, Inc. | Zmodyfikowane białka f rsv i sposoby ich wykorzystania |
| CA2755257A1 (en) | 2009-03-16 | 2010-09-23 | Sanofi Pasteur Biologics Co. | Replication-defective flavivirus vaccine vectors against respiratory syncytial virus |
| WO2010114948A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors |
| SI3178490T1 (sl) | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| CA2781519A1 (en) * | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US20120294889A1 (en) | 2010-11-12 | 2012-11-22 | Paxvax, Inc. | Chimeric Flavivirus Vaccines |
| CA2827375C (en) | 2011-02-14 | 2022-07-19 | The Children's Hospital Of Philadelphia | Improved aav8 vector with enhanced functional activity and methods of use thereof |
| WO2012145509A2 (en) | 2011-04-19 | 2012-10-26 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors, and viruses |
| SI3275892T1 (sl) * | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| CA2849822C (en) | 2011-09-23 | 2021-05-11 | Gary J. Nabel, M.D. | Novel influenza hemagglutinin protein-based vaccines |
| US9506041B2 (en) | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| SI2839014T1 (sl) | 2012-04-18 | 2021-05-31 | The Children's Hospital Of Philadelphia | Sestavek in postopki za zelo učinkovit prenos genov z uporabo variant kapside AAV-JA |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| JP2015529466A (ja) | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター |
| SG10201702292YA (en) | 2012-09-21 | 2017-05-30 | Agency Science Tech & Res | Novel attenuated dengue virus strains for vaccine application |
| BR112015011389A2 (pt) | 2012-11-20 | 2017-08-22 | Glaxosmithkline Biologicals Sa | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica |
| US9624510B2 (en) | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| US9060975B2 (en) | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| US20140271708A1 (en) | 2013-03-15 | 2014-09-18 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G |
| CA2919773A1 (en) | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| EP2974739A1 (en) * | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| CA3033105A1 (en) | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| KR20250011901A (ko) | 2022-03-31 | 2025-01-22 | 더 유니버서티 어브 퀸슬랜드 | 개선된 키메라 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-03-29 BR BR112019019813A patent/BR112019019813A2/pt unknown
- 2018-03-29 EP EP18775234.0A patent/EP3601367B1/en active Active
- 2018-03-29 AU AU2018241252A patent/AU2018241252B2/en active Active
- 2018-03-29 CA CA3057171A patent/CA3057171A1/en active Pending
- 2018-03-29 MX MX2019011599A patent/MX2019011599A/es unknown
- 2018-03-29 SG SG11201908280S patent/SG11201908280SA/en unknown
- 2018-03-29 CN CN201880022016.9A patent/CN110506060B/zh active Active
- 2018-03-29 US US16/498,865 patent/US11254712B2/en active Active
- 2018-03-29 JP JP2019553883A patent/JP7291398B2/ja active Active
- 2018-03-29 WO PCT/AU2018/050299 patent/WO2018176103A1/en not_active Ceased
- 2018-03-29 IL IL269534A patent/IL269534B2/en unknown
- 2018-03-29 PL PL18775234.0T patent/PL3601367T3/pl unknown
- 2018-03-29 DK DK18775234.0T patent/DK3601367T3/da active
- 2018-03-29 KR KR1020197031415A patent/KR20190135017A/ko active Pending
- 2018-03-29 ES ES18775234T patent/ES3001108T3/es active Active
- 2018-03-29 EP EP24205180.3A patent/EP4512820A3/en active Pending
-
2022
- 2022-01-11 US US17/573,616 patent/US12116386B2/en active Active
-
2023
- 2023-03-07 JP JP2023034197A patent/JP2023071901A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515272A5 (enExample) | ||
| US12116386B2 (en) | Chimeric molecules and uses thereof | |
| US7736850B2 (en) | Strain of SARS-associated coronavirus and applications thereof | |
| WO2024109611A1 (zh) | 突变型呼吸道合胞病毒融合前f蛋白及其应用 | |
| JP2010540674A5 (enExample) | ||
| AU2015313650A1 (en) | Flavivirus virus like particle | |
| CA3112040A1 (en) | Compositions and methods for making and using virus-like particles (vlps) | |
| WO2021176397A2 (en) | Expression of sars-cov proteins, nucleic acid constructs, virus like proteins (vlps) and methods relevant thereto | |
| JPWO2020065349A5 (enExample) | ||
| CN117045782A (zh) | 一株自组装的猪冠状病毒新型纳米颗粒疫苗及其应用 | |
| US20230165951A1 (en) | Engineering, production and characterization of plant produced Nucleocapsid and Spike structural proteins of SARS CoV 2 as vaccine candidates against COVID19 | |
| US10377798B2 (en) | Recombinant respiratory syncytial virus G protein fragments | |
| JP2024518548A (ja) | アミノ酸、ヌクレオチドおよびそれを発現するベクター、ならびにサルベコウイルス感染症の予防におけるそれらの使用 | |
| US9907843B2 (en) | Recombinant novirhabdovirus usable as an antigen vector | |
| RU2848308C2 (ru) | Рекомбинантная ДНК psarsN1, рекомбинантная плазмидная ДНК pET-22b-sarsN1, обеспечивающие получение рекомбинантного нуклеокапсидного белка SARSN1 коронавируса, штамм-продуцент E. coli BL21-SARSN1, способный продуцировать рекомбинантный белок SARSN1, иммуногенный в отношении коронавируса SARS-COV-2 | |
| Makdasi et al. | Neutralizing monoclonal anti‐SARS‐CoV‐2 antibodies isolated from immunized rabbits define novel vulnerable spike‐protein epitope. Viruses. 2021; 13 (4): 566 | |
| CN116710128A (zh) | 特异性结合SARSCoV2刺突蛋白的抗体及其制造方法 | |
| CN120608084A (zh) | 一种新型hpv融合蛋白抗原的构建、制备方法及在制备多克隆卵黄抗体中的应用 | |
| within Arenavirus | Identification of an N-Terminal Trimeric | |
| AHMAD-RAUS et al. | LOCALIZATION OF NUCLEOCAPSID (NP) ANTIGENIC SITES BY USING A PANEL OF MONOCLONAL ANTIBODIES AGAINST THE RECOMBINANT NP OF NEWCASTLE DISEASE VIRUS | |
| JP2009106224A (ja) | モノクローナル抗体の作製方法及びそれにより作製されたｈｉｖ−１中和モノクローナル抗体 |